PRESENTED BY:

GUARAV DOSHITARIKA DUGESHAR

PARTH GANDHIHIMANSHU TRIPATHIVINAYAK INDULKAR

Novartis has been in India since 1947.

The Group operates in India through four entities

namely Novartis India Limited, Novartis Healthcare

Private Limited, Sandoz Private Limited and Chiron-

Behring Vaccine Private Limited.

In India Novartis has a presence in pharmaceuticals,

generics (pharmaceutical products that are off patent),

Vaccines, OTC (over-the-counter medicines), eye care.

Mission :- Want to discover , develop, and

successfully market innovative products to prevent

and cure disease , to ease suffering and to enhance

quality of life

Vision :- Want to provide share holder return that

reflect outstanding performance and to adequately

reward those who invest their money, time and

idea in our company.

Novartis Institute for Biomedical Research

NIBR is the global research organization of

Novartis. With more than 6000 scientists and

physicians around the world, NIBR is focused on

discovering new drugs that can change the practice

of medicine.

Increase in R&D spending from US $ 80 million in

2001 to 2.4 billion in 2013.

R&D efforts are guided by two principles:

Do we understand the underlying mechanism

or cause of the disease?

Does this disease represent a significant unmet

medical need in patients?

Novartis is well known for innovation

Novartis has a long-established track record of leadership inpharmaceutical research.

Also leverage this core R&D competence across otherdivisions, sharing research findings and knowledgethroughout organization.

Sandoz, the generics division of Novartis, is the worldleader in biosimilars, oncology injectables, dermatology,ophthalmics, and anti-infectives that have lost patentprotection.

By 2018, patents are scheduled to expire on biologics withglobal sales of more than USD 100 billion and Sandoz iswell-positioned to take full advantage of that opportunity.

Flu and the emerging meningococcal franchise will be keygrowth drivers for the Vaccines Division. The division alsohas a broad pipeline of new vaccines under development.

VACCINES :-

The Novartis influenza vaccines business is among

the world’s largest producers of influenza vaccines

Flucelvax ,Flaud ,Fluvirin

Rabipur from Novartis india contain Vaccines

Rabies

Used in animal bites

Sandoz (Generics)

Sandoz, the generic pharmaceuticals division

of Novartis, is a global industry leader, offering

affordable, high-quality medicines. It is the

third-largest division of Novartis, representing

nearly 16% of the Group’s total net sales.

OTC PRODUCT OF NOVARTIS

Focus on self care brands for consumer

Offering products like

Otrivin (nasal spray)

Voveran cream (analgesic cream)

BUSINESS SEGMENT

PRODUCTNAMES

THERAPEUTIC AREA

COMMENT MARKET SHARE

PHARMA VOVERAN PAIN ANDINFLAMMATOYR

RANK 1 11.4 %

OTRIVIN NASAL SPRAY

RANK 1 27.0 %

MACALVIT CALCIUMSUPPLIMENT

RANK 3 6.9 %

BUSINESS SEGMENT

BRANDS THERAPEUTIC AREA

COMMENTS MARKET SHARE

OTC TOTALSANDOZ BRAND

CALCIUM SUPLLEMENT

RANK 2 14.5%

GENERIC FORISTAL ANTI HISTAMINIC

RANK 1 30 %

Novartis india ltd has 4 manufacturing sites in india approved by

the EU and USFDA

Kolshet:- Houses the sandos devellopment center and Anti TB

formulation plant for global project.

Turbhe:-dedicated cephaloshporins manufacturing site for API &

FDF since 2001

Kalwe :- oral solid dosage plant with capacity of 1 billion unites ,

expansion to 5 billion unites under way

Mahad :- dedicated fermentation plant

Segmental performance

Pharmaceutical Business(contribution 66% )

Sales :- Rs 1552.4mn

Growth :- 13.1 %

OTC Business (Contribution 18% )

Sales :- Rs 422.1 mn

Growth :- 25.9 %

Generic Business ( Contribution 5.7 % )

Sales :- 135mn

Growth :- -4.2%

Animal health business (Contribution 10.2%)

Sales :- 238.8 mn

Growth :- -3.3%

Novartis operates in 140 countries

Company having strong distribution channel

of 20 c&f agents and approximately 250 stokist

in india.

To prevent counterfeiting,Novartis pays much

attention to the distribution process and

channels

•Research and development orientation

•Having research brand in each segmentVALUE

•Global presence in 140 countries

•ALCON surgical division for eye careRARE

•Brand image in all 3 prospects

•Brand as product attributes

•Brand image as organizational attributes

•Brand image as visual imagery

INIMITABLE

•The vision and mission clearly states there orientation towards research and development and bringing innovation to the product which are profitable and will help increase shareholders value

ORGANIZATIONAL SUPPORT/USAGE